Grifols stock gains as Q3 cash flow supports debt reduction

Grifols reported stronger third-quarter results on Monday, November 2, 2026, as growth in its Biopharma business lifted revenue, profitability and cash generation. The company maintained its full-year guidance, while lower leverage strengthened the case for continued debt reduction. The figures and management comments were reported by Yahoo Finance.

Grifols generated third-quarter revenue of 2.04 billion euros, an increase of 8.4 percent at constant currency and above the 1.98 billion euro consensus cited in the report. Net profit rose 27.9 percent to 162 million euros. Adjusted EBITDA increased 9.8 percent at constant currency to 538 million euros, taking the quarterly margin to 26.4 percent.

Biopharma drives quarterly growth

Biopharma revenue grew 10.3 percent at constant currency. Immunoglobulin sales, the company's main growth driver, increased 11.3 percent, while subcutaneous immunoglobulin revenue jumped 40.3 percent. The Alpha-1 and specialty proteins franchise expanded 18.2 percent, supported by rabies-related products.

The product mix was not uniformly positive. Albumin revenue declined 13.2 percent, with regulatory factors and high inventory levels in China weighing on the business. For investors, the contrast leaves Biopharma growth as the main operating support while China remains a relevant risk to the revenue mix.

Cash flow supports deleveraging

Free cash flow before mergers and acquisitions reached 208 million euros in the quarter. The net leverage ratio fell to 3.98 times from 4.2 times a year earlier, and liquidity rose to 2.14 billion euros. Grifols also refinanced its 2027 obligations; the company now faces no significant maturities until the fourth quarter of 2028.

For the first nine months, free cash flow before mergers and acquisitions reached 298 million euros, an increase of 110 million euros from the prior year. Management said the balance-sheet improvement reflected stronger profitability, cash generation and continued execution of its plan. Chief Executive Nacho Abia linked the quarter's performance to growth in core franchises, improving profitability and cash generation, while Chief Financial Officer Rahul Srinivasan highlighted progress on deleveraging and liquidity.

Guidance stays unchanged

Management confirmed its full-year financial guidance after the nine-month performance. The company remains focused on responsible profit growth, cost discipline, margin improvement, free-cash-flow generation and lower leverage. The next investor focus will be whether cash conversion remains strong through the fourth quarter and how quickly the balance sheet continues to improve.

Grifols stock traded at 11.38 euros on Lang & Schwarz at 12:07 CET on Tuesday, November 10, 2026.

Broader market sentiment can be followed in the S&P 500 market.

Topline results from the Phase 3 SPARTA study are expected by the end of the fourth quarter. More news and analyses on Grifols stock.